Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Automatically detect candlestick patterns on any chart

Centessa Pharmaceuticals plc

Contributing Author

Recent Articles by Centessa Pharmaceuticals plc

Jun-22	Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales GlobeNewswire
Feb-03	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Jan-14	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting GlobeNewswire
Dec-11	Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications GlobeNewswire
Nov-11	Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares GlobeNewswire
Nov-11	Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Nov-07	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-05	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program GlobeNewswire
Sep-03	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire
Aug-12	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 GlobeNewswire
Jun-16	Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year GlobeNewswire
May-19	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
May-14	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)